ALB

ALB encodes a multifunctional plasma protein whose biological roles span transport, redox modulation, and tumor suppression, and whose loss has distinct systemic metabolic consequences (PMID:38876053, PMID:42126373). Its immunomodulatory and antioxidant function depends on the redox state of the Cys34 thiol: reduced-thiol albumin suppresses pro-inflammatory and pro-fibrotic macrophage remodeling via MAPK signaling and induces SIRT3, which deacetylates SOD2 to limit mitochondrial ROS and attenuate liver fibrosis, an activity absent in oxidized albumin (PMID:38876053). As a transport protein, functional albumin is required for circulating calcium and vitamin D handling, and missense gain-of-function variants at Arg242 (p.Arg242His) alter thyroid hormone-binding affinity to cause familial dysalbuminemic hyperthyroxinemia, while homozygous or compound heterozygous loss-of-function mutations cause congenital analbuminemia (PMID:27834068, PMID:34142517, PMID:38736368, PMID:31250585). Monogenic ALB loss-of-function additionally produces a distinct form of severe LDL-C elevation, diverging mechanistically from polygenic hypoalbuminemia (PMID:42126373). In cancer, ALB acts as a tumor suppressor: in clear cell renal cell carcinoma its overexpression activates endoplasmic reticulum stress, suppresses EMT, and reprograms glycolysis through negative regulation of SPARC, while its hepatic mRNA expression is destabilized by WTAP-mediated m6A modification in osteosarcoma (PMID:36988233, PMID:36690262, PMID:39862995, PMID:41610717). ALB transcription in hepatocytes is regulated by amino acid availability through C/EBPβ and HNF1A (PMID:32474770).

1. 2010 Low

   Established that some ALB missense variants alter electrophoretic mobility (bisalbuminemia) without affecting ligand binding, defining which structural regions are functionally neutral for steroid and hormone transport.

   Evidence ALB gene sequencing, serum protein electrophoresis, and 3D structural modeling in Korean patients

   PMID:20603593

   Open questions at the time

   • No direct in vitro binding assay or mutagenesis reconstitution
   • Single patient cohort
   • Does not define which residues are critical for binding
2. 2017 Medium

   Identified the molecular basis of familial dysalbuminemic hyperthyroxinemia, showing that gain-of-function ALB variants at Arg242 raise albumin affinity for thyroid hormone and elevate total T4 without true thyroid dysfunction.

   Evidence Sanger sequencing, serum protein electrophoresis, thyroid function testing, and 3D modeling across family members and independent reports

   PMID:27834068 PMID:34142517 PMID:38736368

   Open questions at the time

   • Direct in vitro hormone-binding kinetics of the mutant not measured
   • Quantitative affinity change not established
   • Mechanism of binding-site distortion inferred from modeling only
3. 2019 Low

   Demonstrated that functional albumin is required for systemic calcium and vitamin D transport by linking loss-of-function ALB mutations (congenital analbuminemia) to hypocalcemia and vitamin D deficiency.

   Evidence DNA sequencing and laboratory phenotyping in a patient, with exclusion of secondary hypoalbuminemia

   PMID:31250585

   Open questions at the time

   • Single case report without in vitro mechanistic assay
   • Transport defect inferred from clinical phenotype
   • Variant functional impact not reconstituted
4. 2020 Low

   Showed that hepatocyte ALB expression is controlled by amino acid availability, with ornithine and arginine regulating ALB transcription through C/EBPβ isoforms and HNF1A.

   Evidence Serum-free defined amino acid culture of FLC-4 hepatocellular carcinoma cells with qPCR, ELISA, and Western blotting

   PMID:32474770

   Open questions at the time

   • Single cell line
   • No direct promoter or transcription-factor binding assay
   • Causal role of individual C/EBPβ isoforms not dissected
5. 2023 Medium

   Established post-transcriptional control of ALB by showing WTAP-mediated m6A modification destabilizes ALB mRNA in osteosarcoma, where restored ALB suppresses malignant phenotypes.

   Evidence Me-RIP, dual luciferase reporter, mRNA stability assays, and functional WTAP/ALB knockdown in osteosarcoma cells plus xenograft

   PMID:36690262 PMID:36988233

   Open questions at the time

   • m6A reader mediating decay not identified
   • Mechanism by which ALB suppresses tumor cells not defined here
   • Limited to osteosarcoma context
6. 2024 Medium

   Defined the mechanistic basis of ALB's antioxidant/immunomodulatory activity, showing the Cys34 thiol redox state drives macrophage reprogramming via MAPK and the SIRT3-SOD2 axis to reduce mitochondrial ROS and liver fibrosis.

   Evidence In vitro macrophage assays, MAPK analysis, SIRT3/SOD2 measurements, hepatic stellate cell co-culture, and in vivo mouse liver fibrosis model comparing reduced vs oxidized albumin

   PMID:38876053

   Open questions at the time

   • Direct mechanism linking Cys34 redox state to SIRT3 induction unresolved
   • Receptor/sensor on macrophages not identified
   • Single lab
7. 2025 Medium

   Established ALB as a tumor suppressor in clear cell renal cell carcinoma acting through ERS activation and SPARC-dependent glycolytic reprogramming.

   Evidence ALB overexpression/knockdown in ccRCC lines, metabolic flux (Seahorse) analysis, EMT markers, SPARC knockdown rescue, xenograft, and Mendelian randomization

   PMID:39862995 PMID:41610717

   Open questions at the time

   • Direct physical interaction between ALB and SPARC not shown
   • Mechanism of ERS activation by ALB unclear
   • Single tumor type
8. 2026 Medium

   Demonstrated that monogenic ALB loss-of-function causes a mechanistically distinct form of severe LDL-C elevation, diverging from the reduced LDL-C seen in polygenic hypoalbuminemia.

   Evidence Population biobank cohort study (n>560,000) with genetic variant classification, EHR linkage, and meta-analysis across two independent cohorts

   PMID:42126373

   Open questions at the time

   • Molecular mechanism linking ALB loss to LDL-C elevation not defined
   • No biochemical or cellular model
   • Causal pathway from albumin deficiency to cholesterol handling unknown

• How ALB's transport, redox-signaling, and tumor-suppressive functions are integrated, and the molecular pathway connecting ALB loss to LDL-C elevation, remain unresolved.
• No structural mechanism linking Cys34 redox to downstream signaling
• Mechanism of monogenic ALB-driven hypercholesterolemia unknown
• Direct ALB-SPARC interaction unverified